Biotechnology Valuation: An Introductory Guide (The Wiley Finance Series)

3.25 avg rating
( 4 ratings by Goodreads )
 
9780470511787: Biotechnology Valuation: An Introductory Guide (The Wiley Finance Series)
View all copies of this ISBN edition:
 
 

The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start." -- Chris Blackwell , Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." -- Steve Winokur , Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." -- Dr L.M. Allan , Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." -- Deirdre Y. Gillespie , MD, President & CEO, La Jolla Pharmaceutical Company

"synopsis" may belong to another edition of this title.

From the Back Cover:

Written by experienced financial analyst, Karl Keegan, Biotechnology Valuation: An Introductory Guide is a hands-on guide to the valuation of biotechnology companies both from a private and public market perspective for industry professionals, investors and students.

Focused on product based biotechnology investments and drawing on the author's extensive experience the book begins by valuing healthcare focussed biotechnology companies which are trying to develop new therapeutics using traditional valuation metrics for those readers unfamiliar with finance. The book then takes these principles and applies them to the unique aspects of biotechnology valuation. A background guide to the intricacies of drug development is provided including descriptions of the different clinical phases, relevant regulatory pathways and the attributes that contribute to make a successful drug. The financial analysis and the technical assessment are then combined to take the reader through multiple investment techniques that can applied for biotechnology company valuation including product NPVs, DCF valuation and real options analysis. Real world examples are used throughout the book to illuminate some of the softer aspects of valuation. The book also reviews the different methodologies used for valuing private companies in order to reduce risk and increase returns.

By highlighting some of the most common pitfalls of biotechnology valuation and providing a toolkit to establishing the value of a biotechnology company, Biotechnology Valuation: An Introductory Guide will enable the reader to develop a consistent approach and have a useful toolkit to tackle the valuation of a biotechnology company or individual drug, with confidence.

About the Author:

KARL KEEGAN is currently a managing director and global head of life sciences equity research at CanaccordAdams, a global investment bank focussing on small to mid cap companies. Karl has been a financial analyst covering the biotechnology sector for over eleven years and has previously worked at Dresdner Kleinwort Benson, UBS and Banc of America. Karl and his team have been consistently highly ranked in institutional surveys throughout his career. Prior to embarking on his finance career, Karl completed postdoctoral assignments in the US and UK and worked in the pharmaceutical industry both as a bench scientist and in strategic planning. Dr. Keegan holds a BSc in Pharmacology from University College Dublin, Ireland, MPhil and PhD degrees in Pharmacology from University of Cambridge, UK and MSc in Finance from London Business School, UK. A native of Dublin, Ireland, he now lives in Kent, UK.

"About this title" may belong to another edition of this title.

Top Search Results from the AbeBooks Marketplace

1.

Karl Keegan
Published by John Wiley & Sons Inc, United States (2009)
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Hardcover First Edition Quantity Available: 10
Seller:
Book Depository hard to find
(London, United Kingdom)

Book Description John Wiley & Sons Inc, United States, 2009. Hardback. Condition: New. 1. Auflage. Language: English. Brand new Book. The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns.Keegan's book, punctuated with his personal experience and opinions, is a good place to start." -- Chris Blackwell , Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." -- Steve Winokur , Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." -- Dr L.M. Allan , Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." -- Deirdre Y. Gillespie , MD, President & CEO, La Jolla Pharmaceutical Company. Seller Inventory # LHB9780470511787

More information about this seller | Contact this seller

Buy New
50.97
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

2.

Karl D Keegan
Published by Wiley 2008-11-21, Hoboken, N.J. :|Chichester (2008)
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Hardcover Quantity Available: 10
Seller:
Blackwell's
(Oxford, OX, United Kingdom)

Book Description Wiley 2008-11-21, Hoboken, N.J. :|Chichester, 2008. hardback. Condition: New. Seller Inventory # 9780470511787

More information about this seller | Contact this seller

Buy New
46.52
Convert currency

Add to Basket

Shipping: 4.99
From United Kingdom to U.S.A.
Destination, rates & speeds

3.

Karl Keegan
Published by John Wiley & Sons Inc, United States (2009)
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Hardcover First Edition Quantity Available: 1
Seller:
The Book Depository
(London, United Kingdom)

Book Description John Wiley & Sons Inc, United States, 2009. Hardback. Condition: New. 1. Auflage. Language: English. Brand new Book. The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns.Keegan's book, punctuated with his personal experience and opinions, is a good place to start." -- Chris Blackwell , Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." -- Steve Winokur , Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." -- Dr L.M. Allan , Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." -- Deirdre Y. Gillespie , MD, President & CEO, La Jolla Pharmaceutical Company. Seller Inventory # AAH9780470511787

More information about this seller | Contact this seller

Buy New
51.88
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

4.

Karl Keegan
Published by John Wiley & Sons Inc, United States (2009)
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Hardcover First Edition Quantity Available: 1
Seller:
Book Depository International
(London, United Kingdom)

Book Description John Wiley & Sons Inc, United States, 2009. Hardback. Condition: New. 1. Auflage. Language: English. Brand new Book. The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns.Keegan's book, punctuated with his personal experience and opinions, is a good place to start." -- Chris Blackwell , Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." -- Steve Winokur , Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." -- Dr L.M. Allan , Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." -- Deirdre Y. Gillespie , MD, President & CEO, La Jolla Pharmaceutical Company. Seller Inventory # AAH9780470511787

More information about this seller | Contact this seller

Buy New
54.07
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

5.

Karl Keegan
Published by John Wiley & Sons Inc
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Hardcover Quantity Available: 2
Seller:
THE SAINT BOOKSTORE
(Southport, United Kingdom)

Book Description John Wiley & Sons Inc. Hardback. Condition: New. New copy - Usually dispatched within 2 working days. Seller Inventory # B9780470511787

More information about this seller | Contact this seller

Buy New
53.51
Convert currency

Add to Basket

Shipping: 6.94
From United Kingdom to U.S.A.
Destination, rates & speeds

6.

Keegan, Karl
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Quantity Available: 4
Seller:
GreatBookPrices
(Columbia, MD, U.S.A.)

Book Description Condition: New. Seller Inventory # 4986305-n

More information about this seller | Contact this seller

Buy New
59.98
Convert currency

Add to Basket

Shipping: 2.01
Within U.S.A.
Destination, rates & speeds

7.

Karl Keegan
Published by Wiley (2009)
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Hardcover Quantity Available: 1
Seller:
Ergodebooks
(RICHMOND, TX, U.S.A.)

Book Description Wiley, 2009. Hardcover. Condition: New. 1. Seller Inventory # DADAX0470511788

More information about this seller | Contact this seller

Buy New
66.70
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds

8.

Keegan, Karl
Published by Wiley (2020)
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Hardcover Quantity Available: 3
Print on Demand
Seller:
Murray Media
(NORTH MIAMI BEACH, FL, U.S.A.)

Book Description Wiley, 2020. Hardcover. Condition: New. Never used! This item is printed on demand. Seller Inventory # P110470511788

More information about this seller | Contact this seller

Buy New
67.93
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds

9.

Keegan, Karl
Published by Wiley (2008)
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Hardcover Quantity Available: > 20
Print on Demand
Seller:
California Books
(MIAMI, FL, U.S.A.)

Book Description Wiley, 2008. Condition: New. This book is printed on demand. Seller Inventory # I-9780470511787

More information about this seller | Contact this seller

Buy New
72.88
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds

10.

Keegan, Karl D.
Published by Wiley 2008-12-17 (2008)
ISBN 10: 0470511788 ISBN 13: 9780470511787
New Hardcover Quantity Available: 20
Seller:
Chiron Media
(Wallingford, United Kingdom)

Book Description Wiley 2008-12-17, 2008. Hardcover. Condition: New. Seller Inventory # NU-ING-00168457

More information about this seller | Contact this seller

Buy New
64.70
Convert currency

Add to Basket

Shipping: 9.32
From United Kingdom to U.S.A.
Destination, rates & speeds

There are more copies of this book

View all search results for this book